Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $83,576,000 | $82,295,000 | $80,802,000 | $73,712,000 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Cost of Goods Sold | $37,096,000 | $35,380,000 | $32,522,000 | $32,222,000 |
| Gross Profit | $46,480,000 | $46,915,000 | $48,280,000 | $41,490,000 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| R&D Expenses | $5,786,000 | $5,067,000 | $4,710,000 | $6,106,000 |
| G&A Expenses | $0 | $0 | $0 | -$13,966,000 |
| SG&A Expenses | $38,037,000 | $34,561,000 | $39,206,000 | $35,490,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $49,456,000 |
| Other Operating Expenses | $198,000 | $46,000 | -$29,000 | $122,000 |
| Operating Expenses | $43,823,000 | $39,628,000 | $39,206,000 | $41,596,000 |
| Operating Income | $2,657,000 | $7,287,000 | $9,073,000 | -$106,000 |
| % Margin | 3.2% | 8.9% | 11.2% | -0.1% |
| Other Income/Exp. Net | $1,380,000 | -$1,962,000 | -$2,917,000 | -$824,000 |
| Pre-Tax Income | $4,037,000 | $5,325,000 | $6,156,000 | -$930,000 |
| Tax Expense | $1,164,000 | $2,238,000 | $1,793,000 | $972,000 |
| Net Income | $2,873,000 | $3,087,000 | $4,363,000 | -$1,902,000 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS | 35.05 | 37.66 | 53.22 | -23.2 |
| % Growth | -6.9% | -29.2% | 329.4% | – |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| Weighted Avg Shares Out | 81,967 | 81,976 | 81,978 | 81,980 |
| Weighted Avg Shares Out Dil | 82,095 | 82,095 | 82,088 | 81,980 |
| Supplemental Information | – | – | – | – |
| Interest Income | $743,000 | $718,000 | $555,000 | $434,000 |
| Interest Expense | $85,000 | $62,000 | $47,000 | $22,000 |
| Depreciation & Amortization | $10,597,000 | $743,000 | $6,162,000 | $1,431,000 |
| EBITDA | $15,146,000 | $6,729,000 | $13,306,000 | $1,051,000 |
| % Margin | 18.1% | 8.2% | 16.5% | 1.4% |